Loading...
•
Jun 30, 2021
ACADIA Q2 2021 Earnings Report
Reported a net sales increase in NUPLAZID and provided updates on their pipeline and regulatory interactions.
Key Takeaways
Acadia Pharmaceuticals reported a 5% increase in NUPLAZID net sales for Q2 2021, reaching $115.2 million. The company is engaging with the FDA regarding their DRP program and anticipates top-line results from Phase 3 Rett syndrome and Phase 2 postoperative pain studies by the end of the year. They reduced their full year revenue guidance to $480 to $515 million.
NUPLAZID net sales reached $115.2 million, a 5% increase compared to Q2 2020.
A Type A meeting was held with the FDA regarding pimavanserin for dementia-related psychosis (DRP), with ongoing discussions planned.
Top-line results are expected by the end of the year from the Phase 3 study in Rett syndrome and the Phase 2 study in postoperative pain.
Fiscal year 2021 revenue guidance was reduced to $480 to $515 million.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.com Forward Guidance
Acadia Pharmaceuticals reduced its NUPLAZID net sales guidance for the full year 2021 to $480 to $515 million and decreased GAAP R&D guidance to $250 to $270 million, while reiterating GAAP SG&A guidance at $385 to $415 million.